Zanubrutinib-lenalidomide-rituximab (ZR2) in unfit diffuse large B-cell lymphoma: efficient and tolerant-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Zanubrutinib-lenalidomide-rituximab (ZR2) in unfit diffuse large B-cell lymphoma: efficient and tolerant

Published:2023-11-14 Issue:2 Volume:103 Page:499-510
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Wang Yawen,Xu Jiadai,Li Panpan,Xu Yanyan,Xue Hongwei,Liu Peng^ORCID

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shanghai

Youth Foundation of the Affiliated Hospital of Qingdao University

Cancer Research Foundation of Huiyu Pharmaceutical

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05498-7.pdf

Reference37 articles.

1. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511

2. Wang S, Wang L, Hu J et al (2021) Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China. Cancer Commun (Lond) 41(3):229–239

3. Wu J, Liu C, Tsui ST, Liu D (2016) Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol 9(1):80

4. Wilson WH, Young RM, Schmitz R et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922–926

5. Ioannou N, Jain K, Ramsay AG (2021) Immunomodulatory drugs for the treatment of B cell malignancies. Int J Mol Sci 22(16):8572

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP